Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

Emerg Microbes Infect. 2022 Dec;11(1):1500-1507. doi: 10.1080/22221751.2022.2076613.

Abstract

In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses.

Keywords: SARS-CoV; SARS-CoV-2; heterologous immunization; inactivated vaccine; universal vaccine.

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antibody Formation
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2*
  • Spike Glycoprotein, Coronavirus / genetics
  • Vaccination

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Grants and funding

This study was supported by the National Natural Science Foundation of China (32170941, 82041014), Emergency Key Project of Guangzhou Laboratory (EKPG21-30-2, EKPG21-20). Guangzhou Science and Technology Program key projects (201904020037). Guangzhou Institute of Respiratory Health Open Project (Funds provided by China Evergrande Group, 2020GIRHHMS22, 2020GIRHHMS04). State Key Laboratory of Respiratory Disease (SKLRD-Z-202020), Zhongnanshan Medical Foundation of Guangdong Province (ZNSA-2021005, ZNSA-2022009, ZNSA-2020001), Cultivation Project of the First Affiliated Hospital of Guangzhou Medical University (Project No. ZH202105), Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease (2019B121205010).